Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Hold” by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.4286.

IOVA has been the topic of several recent analyst reports. Truist Financial raised Iovance Biotherapeutics to a “hold” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Finally, Chardan Capital lowered their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, May 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IOVA. KBC Group NV bought a new stake in shares of Iovance Biotherapeutics in the 1st quarter valued at about $34,000. Arcataur Capital Management LLC bought a new position in Iovance Biotherapeutics during the fourth quarter worth about $29,000. Granite Investment Partners LLC bought a new position in Iovance Biotherapeutics during the fourth quarter worth about $29,000. Motley Fool Asset Management LLC acquired a new position in Iovance Biotherapeutics during the fourth quarter worth approximately $29,000. Finally, Sanctuary Advisors LLC acquired a new position in Iovance Biotherapeutics during the first quarter worth approximately $38,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Performance

NASDAQ:IOVA opened at $4.31 on Monday. The stock’s 50-day simple moving average is $3.89 and its 200 day simple moving average is $3.43. The company has a market cap of $1.92 billion, a P/E ratio of -4.54 and a beta of 0.70. Iovance Biotherapeutics has a 52-week low of $1.68 and a 52-week high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The business had revenue of $71.43 million for the quarter, compared to analyst estimates of $77.84 million. During the same quarter in the prior year, the company posted ($0.36) earnings per share. Iovance Biotherapeutics’s revenue was up 44.9% on a year-over-year basis. As a group, equities analysts predict that Iovance Biotherapeutics will post -0.62 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.